Cargando…

Bendectin and Birth Defects : The Challenges of Mass Toxic Substances Litigation /

Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabi...

Descripción completa

Detalles Bibliográficos
Autor principal: Green, Michael D., 1950-
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Philadelphia : University of Pennsylvania Press, 1996.
Colección:Book collections on Project MUSE.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a22000004a 4500
001 musev2_44470
003 MdBmJHUP
005 20230905044644.0
006 m o d
007 cr||||||||nn|n
008 010109s1996 pau o 00 0 eng d
020 |a 9781512816419 
020 |z 9780812216455 
035 |a (OCoLC)966768657 
040 |a MdBmJHUP  |c MdBmJHUP 
100 1 |a Green, Michael D.,  |d 1950- 
245 1 0 |a Bendectin and Birth Defects :   |b The Challenges of Mass Toxic Substances Litigation /   |c Michael D. Green. 
264 1 |a Philadelphia :  |b University of Pennsylvania Press,  |c 1996. 
264 3 |a Baltimore, Md. :  |b Project MUSE,   |c 2017 
264 4 |c ©1996. 
300 |a 1 online resource (384 pages). 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
505 0 0 |t Frontmatter --  |t Contents --  |t Preface --  |t Acknowledgments --  |t Chapter 1. A Birth Defect Child Is Born --  |t Chapter 2. Locating Bendectin Within the Mass Toxic Landscape --  |t Chapter 3. The Science of Determining Toxic Causation --  |t Chapter 4. The Food and Drug Administration --  |t Chapter 5. The Wm. S. Merrell Company --  |t Chapter 6. A Mother's Quest --  |t Chapter 7. The Mekdeci Case --  |t Chapter 8. The Unraveling Of Mekdeci --  |t Chapter 9. The Proliferation of Bendectin Litigation --  |t Chapter 10. Litigating a Multidistrict Case --  |t Chapter 11. The Withdrawal of Bendectin --  |t Chapter 12. Forging a Mass Toxic Substances Trial --  |t Chapter 13. The Settlement and Unsettlement of MDL-486 --  |t Chapter 14. The MDL-486 Trial --  |t Chapter 15. Aggregative Procedure in Mass Toxic Substances Litigation --  |t Chapter 16. The Third Phase of Bendectin Litigation: Oxendine, Richardson, and the Individual Trials --  |t Chapter 17. The Legacy of Bendectin for Toxic Causation Law --  |t Chapter 18. The Lessons and Non-Lessons of Bendectin Litigation --  |t Selected Bibliography --  |t Index 
520 |a Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation, comparing individual and collective forms of litigation, and illustrating the misunderstandings between scientists and lawyers about the role of science in providing evidence for the legal system. 
588 |a Description based on print version record. 
650 7 |a Toxic torts.  |2 fast  |0 (OCoLC)fst01153334 
650 7 |a Products liability  |x Drugs.  |2 fast  |0 (OCoLC)fst01078391 
650 7 |a Complex litigation.  |2 fast  |0 (OCoLC)fst00871591 
650 7 |a Bendectin (Trademark)  |x Toxicology.  |2 fast  |0 (OCoLC)fst00830294 
650 7 |a Abnormalities, Human.  |2 fast  |0 (OCoLC)fst00794451 
650 7 |a POLITICAL SCIENCE  |x Government  |x Judicial Branch.  |2 bisacsh 
650 7 |a LAW  |x Legal Services.  |2 bisacsh 
650 7 |a LAW  |x Civil Procedure.  |2 bisacsh 
650 7 |a LAW  |x Administrative Law & Regulatory Practice.  |2 bisacsh 
650 6 |a Instances complexes  |z États-Unis. 
650 6 |a Responsabilite pour dommages causes par les substances dangereuses  |z États-Unis. 
650 6 |a Responsabilite du fait des produits  |x Medicaments  |z États-Unis. 
650 2 2 |a Pyridoxine  |x legislation & jurisprudence 
650 2 2 |a Pyridoxine  |x adverse effects 
650 2 2 |a Doxylamine  |x legislation & jurisprudence 
650 2 2 |a Doxylamine  |x adverse effects 
650 1 2 |a Consumer Product Safety  |x legislation & jurisprudence 
650 1 2 |a Abnormalities, Drug-Induced  |x legislation & jurisprudence 
650 0 |a Abnormalities, Human. 
650 0 |a Bendectin (Trademark)  |x Toxicology. 
650 0 |a Complex litigation  |z United States. 
650 0 |a Toxic torts  |z United States. 
650 0 |a Products liability  |x Drugs  |z United States. 
651 7 |a United States.  |2 fast  |0 (OCoLC)fst01204155 
651 2 |a United States 
655 7 |a Electronic books.   |2 local 
710 2 |a Project Muse.  |e distributor 
830 0 |a Book collections on Project MUSE. 
856 4 0 |z Texto completo  |u https://projectmuse.uam.elogim.com/book/44470/ 
945 |a Project MUSE - Custom Collection 
945 |a Project MUSE - Archive Complete Supplement V 
945 |a Project MUSE - Archive Political Science and Policy Studies Supplement V